The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis

[1] Kurki P(2021)Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective Drugs 33 621-634

[2] Barry S(2019)Evolution of the EU biosimilar framework: past and future BioDrugs 34 1128-1144

[3] Bourges I(2017)The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries Adv Ther 40 1722-1760

[4] Tsantili P(2020)Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs 32 681-691

[5] Wolff-Holz E(2022)Biopharmaceutical benchmarks 2022 Nat Biotechnol 12 1-12

[6] Wolff-Holz E(2014)Barriers to the uptake of biosimilars and possible solutions: a Belgian case study Pharmacoeconomics 14 352-309

[7] Tiitso K(2020)Biosimilars in Belgium: a proposal for a more competitive market Acta Clin Belg 27 299-956

[8] Vleminckx C(2021)Off-patent biological and biosimilar medicines in Belgium: a market landscape analysis Front Pharmacol 68 950-355

[9] Weise M(2021)The off-patent biological market in Belgium: is the health system creating a hurdle to fair market competition? Pharmaceuticals 46 348-83

[10] Gulácsi L(2002)Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 21 58-744

[1] Kurki P(2021)Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective Drugs 33 621-634

[2] Barry S(2019)Evolution of the EU biosimilar framework: past and future BioDrugs 34 1128-1144

[3] Bourges I(2017)The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries Adv Ther 40 1722-1760

[4] Tsantili P(2020)Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs 32 681-691

[5] Wolff-Holz E(2022)Biopharmaceutical benchmarks 2022 Nat Biotechnol 12 1-12

[6] Wolff-Holz E(2014)Barriers to the uptake of biosimilars and possible solutions: a Belgian case study Pharmacoeconomics 14 352-309

[7] Tiitso K(2020)Biosimilars in Belgium: a proposal for a more competitive market Acta Clin Belg 27 299-956

[8] Vleminckx C(2021)Off-patent biological and biosimilar medicines in Belgium: a market landscape analysis Front Pharmacol 68 950-355

[9] Weise M(2021)The off-patent biological market in Belgium: is the health system creating a hurdle to fair market competition? Pharmaceuticals 46 348-83

[10] Gulácsi L(2002)Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 21 58-744